key: cord-1014361-b6pim5tx
authors: Chen, Yi-Hsuan; Fang, Chi-Tai
title: A Simple Rule for Interpreting COVID-19 Antibody Test Results, by Seroprevalence and Vaccination Status
date: 2021-02-27
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2021.02.008
sha: 8601816f019f33796cc545384ce75841e3634898
doc_id: 1014361
cord_uid: b6pim5tx

nan

Dear editor, 1 2 A positive COVID-19 antibody (serological) test result supposedly indicates immunity, 3 safety for business travel, and no need for further vaccination. False positive results, however, 4 will mislead important decisions. 5

Risk of false positive results is not only determined by specificity/sensitivity but also by 6 prevalence. 1 Prevalence of COVID-19 antibody is estimated by seroprevalence surveys using a 7 serological test. Nevertheless, since the serological test itself is not perfect, the seroprevalence 8 can be substantially different from the true prevalence. 9

Theoretically, the (unadjusted) seroprevalence should be no less than one minus 10 specificity and no larger than sensitivity. If one knows exact sensitivity and specificity, it is 11 feasible to calculate the true prevalence by adjusting seroprevalence with sensitivity and 12 specificity. However, sensitivity and specificity information provided by the manufacturers can 13 be over-optimistic, because the United States Food and Drug Administration (FDA) Emergency 14

Use Authorization (EUA) for COVID-19 serological test does not require the demonstration of a 15 lack of cross-reactions with common cold coronaviruses (e.g. HKU1, NL63, OC43, 229E). 2,3 16

If the exact sensitivity and specificity of a test are uncertain, it is still possible to estimate 17 sensitivity, specificity, and prevalence using one of latent class model-based numerical methods. 4 18 But this approach is cumbersome, and not suitable for practical use. 19

To develop a simple and accurate rule for correct interpretation of COVID-19 serological 20 test results, we solve for the probability that a positive result is false (false discovery rate, FDR), 21 in terms of crude (unadjusted) seroprevalence, for EUA authorized COVID-19 serological tests 22 (≥95% specificity and ≥90% sensitivity): 3 (Supplementary Appendix): 23

Figure shows that, when the crude (unadjusted) seroprevalence is higher than 9.5%, an 1 EUA authorized COVID-19 serological test offers clinically meaningful positive test results 2 (more likely to be true positive than to be false positive). Confirmation with a second test 3 (orthogonal testing algorithm) will further improve the PPV. 1 However, when crude 4 seroprevalence is between 2.0% and 9.5%, the chance of a false positive result varies from less 5 than 10% (when specificity is 99% and sensitivity is 99%) to nearly 100% (when specificity is 6 95% and sensitivity is 90%). In such seroprevalence range, interpretation of serological test 7 results highly depends on the specificity of test kits used. For settings with a crude 8 seroprevalence lower than 2.0%, serological testing using a test kit with a specificity of less than 9 99% are not advisable due to a nearly 100% false positive rate. On the other hand, since 10 authorized COVID-19 vaccines are expected to yield a protective antibody response in ≥ 70% 11 vaccinees 5 , the risk of false positive result will be less than 1.7% for an EUA antibody test 12 ( Figure) . 13

Our results show that, for an unvaccinated person from settings with seroprevalence less 14 than 9.5% and without a history of PCR-confirmed COVID-19, a positive COVID- 19 

Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody 4 testing

Food and Drugs Administration. Umbrella letter to manufacturers of In vitro diagnostic 10

SARS-CoV-2 antibody tests on issurance of Emergence Use Authorization

Estimation of diagnostic test accuracy without full verification: a 13 review of latent class methods

Safety and efficacy of the ChAdOx1 nCoV-15 19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised 16 controlled trials in Brazil, South Africa, and the UK. The